Share
37,911 Posts.
lightbulb Created with Sketch. 828
clock Created with Sketch. 28/01/21
10:33
Share
Originally posted by Eqz
↑
Disappointing revenue from analytics services and does sound like COVID has significantly impacted our commercialization efforts.The necessity for clinical pathology laboratories to focus testing on the SARS-CoV-2 virus has naturally restricted testing for other diseases. This has presented limitations for the immediate rollout of the novel PromarkerD test, and there have been impacts in each country (Spain, Mexico, Dominican Republic, Italy, Israel) where Proteomics International has a licence or distributionTo this end Proteomics International is in discussions for the manufacture of PromarkerD to be relocated to the northern hemisphere, and is pursuing regulatory and reimbursement pathways in a number of jurisdictions . The Company will adjust timelines and provide details where they are material to achieving roll-outs in a specified time period. has the potential to overtake current immunoassay technology and assume mainstream use in clinical pathology laboratories . Exemplifying this, the Clinical Proteomics publication [ASX: 5 November] is one of the first validations of a proteomics derived multi-biomarker diagnostic test in a clinical setting.
Expand
thanks for the yellowed highlights for us lazy ones
(20min delay)